EVLO vs. EVFM, SBFM, SPRC, HSTO, LSDI, BLPH, CMRA, GRI, ADTX, and NBSE
Should you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Evofem Biosciences (EVFM), Sunshine Biopharma (SBFM), SciSparc (SPRC), Histogen (HSTO), Lucy Scientific Discovery (LSDI), Bellerophon Therapeutics (BLPH), Comera Life Sciences (CMRA), GRI Bio (GRI), Aditxt (ADTX), and NeuBase Therapeutics (NBSE). These companies are all part of the "pharmaceutical preparations" industry.
Evelo Biosciences (NASDAQ:EVLO) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
Evofem Biosciences has a net margin of 315.54% compared to Evelo Biosciences' net margin of 0.00%. Evelo Biosciences' return on equity of 0.00% beat Evofem Biosciences' return on equity.
Evofem Biosciences has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks.
Evelo Biosciences has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500.
Evofem Biosciences received 92 more outperform votes than Evelo Biosciences when rated by MarketBeat users. Likewise, 69.50% of users gave Evofem Biosciences an outperform vote while only 60.50% of users gave Evelo Biosciences an outperform vote.
In the previous week, Evofem Biosciences had 1 more articles in the media than Evelo Biosciences. MarketBeat recorded 3 mentions for Evofem Biosciences and 2 mentions for Evelo Biosciences. Evelo Biosciences' average media sentiment score of 0.32 beat Evofem Biosciences' score of 0.16 indicating that Evelo Biosciences is being referred to more favorably in the media.
0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 0.2% of Evofem Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Evofem Biosciences beats Evelo Biosciences on 9 of the 14 factors compared between the two stocks.
Get Evelo Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evelo Biosciences Competitors List
Related Companies and Tools
